CN106727643A - A kind of Western medicine for treating bacterial pneumonia - Google Patents
A kind of Western medicine for treating bacterial pneumonia Download PDFInfo
- Publication number
- CN106727643A CN106727643A CN201611171800.5A CN201611171800A CN106727643A CN 106727643 A CN106727643 A CN 106727643A CN 201611171800 A CN201611171800 A CN 201611171800A CN 106727643 A CN106727643 A CN 106727643A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- bacterial pneumonia
- cimigenoside
- isoschaftoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Western medicine for treating bacterial pneumonia, the Western medicine of the treatment bacterial pneumonia is according to the primary raw material of weight portion：26 parts of cimigenoside, 36 40 parts of halofuginone hydrobromide, 26 parts of different sinensetin, 6 10 parts of geraniin, 25 30 parts of poncirin, 7 14 parts of arecaline, 23 parts of cucurbitacin IIA, 6 29 31 parts of asafoetide acyl spinosins, 24 parts of Isoschaftoside, 24 parts of 3 hydroxyl morindone, 0.1 0.6 parts of tracheloside.Medicine of the present invention is strictly selected material composition according to the understanding mechanism of bacterial pneumonia, so as to reach the purpose of comprehensive rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Western medicine for treating bacterial pneumonia.
Background technology
Bacterial pneumonia is most common pneumonia, is also one of most common infectious diseases.It mainly includes pneumonia chain
Coccus, staphylococcus aureus, α-hemolytic streptococcus, klebsiella pneumoniae, haemophilus influenzae, pseudomonas aeruginosa
Pneumonia etc..Health threat to children and the elderly is very big.By anatomical classification, pneumonia can be divided into great Ye, it is lobular and
Matter.It is now to press etiological classification, main infectious and physics and chemistry such as radioactive ray, poison gas, medicine and metamorphosis for ease for the treatment of more
Reactivity such as hylactic pneumonia, it is bacterium, virus, Chlamydia, mycoplasma, Richettsia, fungi that clinical findings is most
The infectious pneumonia caused with parasite etc., wherein most commonly seen with bacterium.The pathogen of pneumonia is because of age, with disease
With immune functional state, acquisition pattern and have larger difference.The common causative of community acquired pneumonia is streptococcus pneumonia, stream
Haemophilus influenza, staphylococcus aureus, micrococcus scarlatinae, Legionella, anaerobic bacteria and virus, mycoplasma and Chlamydia
Deng, and then with Pseudomonas aeruginosa and other pseudomonads, pneumobacillus, Escherichia coli, cloaca and generation intestines bar in nosocomial pneumonia in patients
Bacterium, proteus, Methicillin-resistant Staphylococcus aureus (MRSA) and fungi etc. are common.Most of aspiration pneumonia is anaerobic infection.
Lack effective medicine at present.
The content of the invention
It is an object of the invention to provide a kind of Western medicine for treating bacterial pneumonia, to solve to be proposed in above-mentioned background technology
Problem.
To achieve the above object, the present invention provides following technical scheme：
A kind of Western medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：Cimigenoside 2-6 parts, often
36-40 parts of mountain ketone, different sinensetin 2-6 parts, geraniin 6-10 parts, poncirin 25-30 parts, arecaline 7-14 parts, cucurbitacin IIA
2-3 parts, 29-31 parts of 6- asafoetides acyl spinosin, Isoschaftoside 2-4 parts, 2-4 parts of 3- hydroxyl morindones, tracheloside 0.1-0.6
Part.
As further scheme of the invention：The Western medicine of the treatment bacterial pneumonia, according to the primary raw material of weight portion
For：Cimigenoside 3-5 parts, halofuginone hydrobromide 38-39 parts, different sinensetin 3-5 parts, geraniin 7-9 parts, poncirin 26-28 parts,
Arecaline 9-12 parts, 2-3 parts of cucurbitacin IIA, 29-31 parts of 6- asafoetides acyl spinosin, Isoschaftoside 2-4 parts, 3- hydroxyl bars
2-4 parts, tracheloside 0.2-0.5 parts of halberd quinone.
As further scheme of the invention：The Western medicine of the treatment bacterial pneumonia, according to the primary raw material of weight portion
For：4 parts of cimigenoside, 39 parts of halofuginone hydrobromide, 4 parts of different sinensetin, 8 parts of geraniin, 27 parts of poncirin, 11 parts of arecaline,
3 parts of cucurbitacin IIA, 30 parts of 6- asafoetide acyls spinosin, 3 parts of Isoschaftoside, 3 parts of 3- hydroxyls morindone, 0.4 part of tracheloside.
A kind of preparation method of the Western medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cimigenoside, halofuginone hydrobromide, different sinensetin, old is weighed by above-mentioned metering ratio
Stork grass element, poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, trachelospermum jasminoide
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4-8min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of bacterial pneumonia to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of bacterial pneumonia, so as to reach comprehensively
The purpose of rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of Western medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：2 parts of cimigenoside, Changshan
36 parts of ketone, 2 parts of different sinensetin, 6 parts of geraniin, 25 parts of poncirin, 7 parts of arecaline, 2 parts of cucurbitacin IIA, 6- asafoetides acyl this
29 parts of skin promise element, 2 parts of Isoschaftoside, 2 parts of 3- hydroxyls morindone, 0.1 part of tracheloside.
A kind of preparation method of the Western medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cimigenoside, halofuginone hydrobromide, different sinensetin, old is weighed by above-mentioned metering ratio
Stork grass element, poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, trachelospermum jasminoide
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of bacterial pneumonia to temperature control.
Embodiment 2
A kind of Western medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：3 parts of cimigenoside, Changshan
38 parts of ketone, 3 parts of different sinensetin, 7 parts of geraniin, 26 parts of poncirin, 9 parts of arecaline, 2 parts of cucurbitacin IIA, 6- asafoetides acyl this
29 parts of skin promise element, 2 parts of Isoschaftoside, 2 parts of 3- hydroxyls morindone, 0.2 part of tracheloside.
A kind of preparation method of the Western medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cimigenoside, halofuginone hydrobromide, different sinensetin, old is weighed by above-mentioned metering ratio
Stork grass element, poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, trachelospermum jasminoide
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of bacterial pneumonia to temperature control.
Embodiment 3
A kind of Western medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：4 parts of cimigenoside, Changshan
39 parts of ketone, 4 parts of different sinensetin, 8 parts of geraniin, 27 parts of poncirin, 11 parts of arecaline, 3 parts of cucurbitacin IIA, 6- asafoetides acyl this
30 parts of skin promise element, 3 parts of Isoschaftoside, 3 parts of 3- hydroxyls morindone, 0.4 part of tracheloside.
A kind of preparation method of the Western medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cimigenoside, halofuginone hydrobromide, different sinensetin, old is weighed by above-mentioned metering ratio
Stork grass element, poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, trachelospermum jasminoide
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 6min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 6 DEG C, packaging obtains final product the Western medicine for the treatment of bacterial pneumonia to temperature control.
Embodiment 4
A kind of Western medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：5 parts of cimigenoside, Changshan
39 parts of ketone, 5 parts of different sinensetin, 9 parts of geraniin, 28 parts of poncirin, 12 parts of arecaline, 3 parts of cucurbitacin IIA, 6- asafoetides acyl this
31 parts of skin promise element, 4 parts of Isoschaftoside, 4 parts of 3- hydroxyls morindone, 0.5 part of tracheloside.
A kind of preparation method of the Western medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cimigenoside, halofuginone hydrobromide, different sinensetin, old is weighed by above-mentioned metering ratio
Stork grass element, poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, trachelospermum jasminoide
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of bacterial pneumonia to temperature control.
Embodiment 5
A kind of Western medicine for treating bacterial pneumonia, be according to the primary raw material of weight portion：6 parts of cimigenoside, Changshan
40 parts of ketone, 6 parts of different sinensetin, 10 parts of geraniin, 30 parts of poncirin, 14 parts of arecaline, 3 parts of cucurbitacin IIA, 6- asafoetide acyls
31 parts of spinosin, 4 parts of Isoschaftoside, 4 parts of 3- hydroxyls morindone, 0.6 part of tracheloside.
A kind of preparation method of the Western medicine for treating bacterial pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cimigenoside, halofuginone hydrobromide, different sinensetin, old is weighed by above-mentioned metering ratio
Stork grass element, poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, trachelospermum jasminoide
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of bacterial pneumonia to temperature control.
Pharmacology test
1st, chronic toxicity test
It is experiment with Western medicine obtained in the embodiment of the present invention 3, using gastric infusion mode, successive administration 2 times in 24h,
Per minor tick 8h, 400mg/kg doses are administered every time, daily accumulation medicine total amount reaches 800mg medicines/kg, it is clinical equivalent to people to use
100 times of amount.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, and hair color light, its average weight is equal
Increase with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain, thymus gland,
Stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：Western medicine of the present invention without
Chronic toxicity.
2nd, long term toxicity test
It is experiment with Western medicine obtained in the embodiment of the present invention 3, using gastric infusion mode, Western medicine of the present invention is divided into low dose
Amount, middle dosage, three groups of high dose, the drug dose of each group is respectively 80,160,240mg medicines/kg/d, equivalent to clinical dosage
10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical
Mark without obvious influence, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2
Also substantially change is had no week.Result shows：Western medicine of the present invention does not find overt toxicity reaction and postpones in long term toxicity test
Toxic reaction.It can be seen that, Western medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical test
In April, 2015, in Nanjing, 200 patients screened in hospital in May, 2015, and all patients meet bacillary lung
Scorching illness.Wherein male 105, women 95, minimal ages 8 years old, max age 75 years old, average age 41.7 years old.All trouble
Person takes the Western medicine of the preparation of the embodiment of the present invention 3, and instructions of taking is：Daily 8mg/kg, 3 days courses for the treatment of treat two treatments altogether
Journey.
Diagnostic criteria：(1) chest X-ray：It is most common to show as the change of Bronchopneumonia type, generally it is helpless to pneumonia disease
The determination of original, but some features can have suggested to diagnosis, and such as lobe of the lung consolidation, cavity formation or relatively large pleural effusion are more common in
Bacterial pneumonia.Staphylococcal pneumonia can cause obvious lung tissue necrosis, lung qi capsule, pulmonary abscess and pyothorax.Grain-negative bar
Bacterium pneumonia is often in LLB pneumonia type, easily forms multiple small vomica.(2) bacteriology checking：Phlegm or hydrothorax plate coating checking,
Culture pathogenic bacteria and antibiotic sensitivity test are for continuous 2,3 times same bacterial growth, and the possibility of pathogenic bacteria is big, only once sun
Property or be repeatedly different bacterium growth, then poor reliability.Bacterial concentration >=107Cfa/ml is pathogenic bacteria, 105~107Cfa/ml is
It is suspicious,<105Cfa/ml is generally contaminated bacteria.(3) blood test：White blood cell count(WBC) and neutrophil leucocyte generally increase, and can have core
Move to left, old or several cases white blood cell count(WBC) can not increase.(4) immunologic test：With immunofluorescence, enzyme linked immunological suction
The methods such as adhesion test, counter immunoelectrophoresis detect the antigen or antibody of serum pathogen, help diagnosis.Polymerase chain reaction is to disease
The detection of substance has certain meaning.(5) other check the correlations such as row blood gas analysis if necessary, Liver and kidney function, serum electrolyte
Check.
Curative effect determinate standard：Clinical symptoms all disappear, and laboratory checks normal.Take a turn for the better：Clinical symptom relief, the state of an illness is obtained
To control, laboratory examination improvement or normal.It is invalid：No significant improvement or aggravated in clinical symptoms.
Therapeutic effect：200 patients, cure 168, take a turn for the better 20, invalid 12, total effective rate 94.0%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. a kind of Western medicine for treating bacterial pneumonia, it is characterised in that the primary raw material according to weight portion is：Cimigenoside
2-6 parts, halofuginone hydrobromide 36-40 parts, different sinensetin 2-6 parts, geraniin 6-10 parts, poncirin 25-30 parts, arecaline 7-14 parts,
2-3 parts of cucurbitacin IIA, 29-31 parts of 6- asafoetides acyl spinosin, Isoschaftoside 2-4 parts, 2-4 parts of 3- hydroxyl morindones, network
0.1-0.6 parts of stone glycosides.
2. it is according to claim 1 treatment bacterial pneumonia Western medicine, it is characterised in that the treatment bacterial pneumonia
Western medicine, be according to the primary raw material of weight portion：Cimigenoside 3-5 parts, halofuginone hydrobromide 38-39 parts, different sinensetin 3-5 parts, it is old
Stork grass 7-9 parts of element, poncirin 26-28 parts, arecaline 9-12 parts, 2-3 parts of cucurbitacin IIA, 6- asafoetide acyl spinosins 29-31
Part, Isoschaftoside 2-4 parts, 2-4 parts, tracheloside 0.2-0.5 parts of 3- hydroxyl morindones.
3. it is according to claim 1 and 2 treatment bacterial pneumonia Western medicine, it is characterised in that the bacillary lung for the treatment of
Scorching Western medicine, be according to the primary raw material of weight portion：4 parts of cimigenoside, 39 parts of halofuginone hydrobromide, 4 parts of different sinensetin, geranium wilfordii
Element 8 parts, 27 parts of poncirin, 11 parts of arecaline, 3 parts of cucurbitacin IIA, 30 parts of 6- asafoetide acyls spinosin, 3 parts of Isoschaftoside,
3 parts of 3- hydroxyls morindone, 0.4 part of tracheloside.
4. it is a kind of as described in claim 1-3 is any treatment bacterial pneumonia Western medicine preparation method, it is characterised in that tool
Body step is：
First, in pharmaceutical grade clean area, cimigenoside, halofuginone hydrobromide, different sinensetin, geranium wilfordii are weighed by above-mentioned metering ratio
Element, poncirin, arecaline, cucurbitacin IIA, 6- asafoetide acyl spinosin, Isoschaftoside, 3- hydroxyls morindone, tracheloside, mistake
Sieve, machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 4-8min, controls RSD≤5%, and compressing tablet is simultaneously after mixing
Low temperature drying, at 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of bacterial pneumonia to temperature control.
5. it is according to claim 4 treatment bacterial pneumonia Western medicine preparation method, it is characterised in that in specific steps
Mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171800.5A CN106727643A (en) | 2016-12-17 | 2016-12-17 | A kind of Western medicine for treating bacterial pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171800.5A CN106727643A (en) | 2016-12-17 | 2016-12-17 | A kind of Western medicine for treating bacterial pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727643A true CN106727643A (en) | 2017-05-31 |
Family
ID=58892063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611171800.5A Pending CN106727643A (en) | 2016-12-17 | 2016-12-17 | A kind of Western medicine for treating bacterial pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727643A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111411099A (en) * | 2020-05-14 | 2020-07-14 | 云南农业大学 | Hemsleya amabilis acetyl transferase, coding gene thereof and application of hemsleya amabilis acetyl transferase in preparation of cucurbitacin |
-
2016
- 2016-12-17 CN CN201611171800.5A patent/CN106727643A/en active Pending
Non-Patent Citations (8)
| Title |
|---|
| AM EI-SHAFA: "Bioactive polymethoxyflavones and flavanone glycosides from the peels of Citrus deliciosa", 《CHINESE PHARMACEUTICAL JOURNAL》 * |
| BINFENG CHENG等: "Dual-bioactivity-based liquid chromatography-coupled quadrupole time-of-flight mass spectrometry for NF-κB inhibitors and β2AR agonists identification in Chinese Medicinal Preparation Qingfei Xiaoyan Wan", 《ANAL BIOANAL CHEM》 * |
| CHINEDU P.ANOKWURU等: ""Antibacterial and antioxidant constituents of Acalypha wilkesiana", 《NATURAL PRODUCT RESEARCH》 * |
| MARTIN HANSEN等: "Fate and antibacterial potency of anticoccidial drugs and their main abiotic degradation products", 《ENVIRONMENTAL POLLUTION》 * |
| 刘振鹏: "铁皮石斛不同家系叶片主要功效成分变异规律研究", 《中国优秀硕士学位论文全文数据库农业科技辑》 * |
| 师超等: "HPLC 测定大鼠血浆中雪胆甲素的浓度及其药动学研究", 《中国药师》 * |
| 朱晓艳: "瓯柑果实黄酮类化合物的分离鉴别及相关活性研究", 《中国优秀硕士学位论文全文数据库农业科技辑》 * |
| 邓天好等: "四磨汤对便秘肠道微生态调节作用的研究", 《中国微生态学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111411099A (en) * | 2020-05-14 | 2020-07-14 | 云南农业大学 | Hemsleya amabilis acetyl transferase, coding gene thereof and application of hemsleya amabilis acetyl transferase in preparation of cucurbitacin |
| CN111411099B (en) * | 2020-05-14 | 2022-09-27 | 云南农业大学 | Hemsleya amabilis acetyl transferase, coding gene thereof and application of hemsleya amabilis acetyl transferase in preparation of cucurbitacin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2826473B1 (en) | Antibacterial use of patchoulol | |
| CN105746606A (en) | Clinical laboratory indoor disinfector and preparation method thereof | |
| CN103169737B (en) | Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| Otieno et al. | Multi-plant or single-plant extracts, which is the most effective for local healing in Tanzania? | |
| CN101053600B (en) | Medicinal composition for treating cough and preparation method and application thereof | |
| CN103933350B (en) | Use of rhizoma bletillae ethyl acetate extract | |
| CN104225403B (en) | One kind treats phthisical pharmaceutical composition and preparation method and purposes | |
| CN106727643A (en) | A kind of Western medicine for treating bacterial pneumonia | |
| CN101972391A (en) | Medicinal composition used for treating swine mastitis and preparation method thereof | |
| CN101537011B (en) | Pharmaceutical composition for preventing or treating parkinsonism and preparation method thereof | |
| CN106727971A (en) | A kind of medicine for treating bacterial pneumonia | |
| CN103251691B (en) | Chinese medicine formula for treating bovine mastitis as well as extract and preparation thereof | |
| CN106728302A (en) | A kind of Chinese and Western medicine combination for treating bacterial pneumonia and preparation method thereof | |
| CN113116938A (en) | Quadruple viable bacteria preparation and application thereof | |
| CN101810675A (en) | Medicament for treating pharyngitis | |
| CN113662950B (en) | Application of saponin in preparation of anti-mycoplasma bovis product | |
| CN103263523B (en) | A kind of for breast perfusion preparation preventing and treating mastitis and preparation method thereof | |
| CN104055981B (en) | One kind treats bronchiectasic Chinese medicine composition | |
| CN104689129A (en) | Anti-tuberculous traditional Chinese medicine fritillary and burdock fruit tuberculosis-eliminating extractive and application | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN106727508A (en) | A kind of combination drug for treating chronic dysentery | |
| CN105030882A (en) | Medicine compound preparation for preventing and treating respiratory diseases of livestock and poultry, and preparation method thereof | |
| CN104435040A (en) | Balsamiferou blumea herb and fosfomycin containing compound medicine for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |